One of the standouts of today's afternoon trading session was BridgeBio Pharma, which logged a 3.1% performance and outperformed the S&P 500 by 3.0%. The Pharmaceutical stock is now trading at $47.91 per share and may still have upside potential because it is still -19.66% under its average target price of $59.63. Analysts have set target prices ranging from $41.0 to $95.0 dollars per share, and have given the stock an average rating of buy.
The market, on the other hand, is a bit more pessimistic. BridgeBio Pharma's short interest -- meaning the percentage of its share float that is being shorted on an expectation of a price decline -- is quite high at 18.8%. The float includes only shares that are available for public trading, and excludes preferred shares.
When a stock is sold short, it means an investor has borrowed shares of the stock from their broker, and then sold them at the going market price. The investor hopes for the price to decline, so that they might buy those shares back at a lower price in the future. Once they do, they can return the borrowed shares to their broker, and keep the profit they made on the transaction.
Another way to gauge the sentiment on BridgeBio Pharma is to look at the percentage of institutions that are invested in the stock. In this case, 98.1% of the shares are held by pension, mutual, and hedge funds, which shows that these institutions probably have strong confidence in the stock.
If institutions are invested in a particular stock, it shows in most cases that they have performed quality research and concluded that it is a good investment. In some cases, however, increases in institutional ownership could be a sign of a takeover attempt or proxy fight, which can actually injure share prices. Also, institutions are not infallible, and can certainly make miscalculations -- often with spectacular results.
Overall, there is mixed market sentiment on BridgeBio Pharma because its an analyst consensus of some upside potential, a buy rating, an unusually large proportion of its shares sold short, and a significant number of institutional investors. Warren Buffett famously said that in the short term, markets are voting mechanisms, but in the long term, they are weighing mechanisms. This means that long term investors should be aware of a stock's fundamentals before committing.
Buffett was one of the fist investors to focus on free cash flow as a yardstick for a company's health. Here are BBIO's recent cash flows:
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | -520,726 | 933 | -521,659 | 1.39 |
| 2023 | -527,720 | 1,306 | -529,026 | -24.68 |
| 2022 | -419,494 | 4,821 | -424,315 | 16.99 |
| 2021 | -497,934 | 13,246 | -511,180 | -25.53 |
| 2020 | -399,714 | 7,518 | -407,232 | -58.94 |
| 2019 | -253,587 | 2,638 | -256,225 |
